Get started
Keyword

prasugrel

Description: Prasugrel is an antiplatelet medication that blocks the P2Y12 receptor to reduce blood clot formation, particularly in patients with acute coronary syndrome.
Wikidata ID: wiki/Q416232
OpenAlex ID: keywords/prasugrel
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 · Stephen D. Wiviott, Eugene Braunwald, et al. · New England Journal of Medicine · 6,810
PDF
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
2014 · Laura Mauri, Dean J. Kereiakes, et al. · New England Journal of Medicine · 1,929
PDF
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
1998 · Martin B. Leon, Donald S. Baim, et al. · New England Journal of Medicine · 1,815
PDF
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial
2015 · Marco Valgimigli, Andrea Gagnor, et al. · The Lancet · 1,303
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
2009 · Gilles Montalescot, Stephen D Wiviott, et al. · The Lancet · 1,068
Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting
2012 · Jean-Philippe Collet, Thomas Cuisset, et al. · New England Journal of Medicine · 887
PDF
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
2012 · Matthew T. Roe, Paul W. Armstrong, et al. · New England Journal of Medicine · 878
PDF
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
2019 · Stefanie Schüpke, Franz-Josef Neumann, et al. · New England Journal of Medicine · 819
PDF
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
2008 · Stephen D. Wiviott, Eugene Braunwald, et al. · Circulation · 759
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007 · J.T. BRANDT, S.L. CLOSE, et al. · Journal of Thrombosis and Haemostasis · 734
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
2009 · Michelle L O'Donoghue, Eugene Braunwald, et al. · The Lancet · 725
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
2013 · Gilles Montalescot, Leonardo Bolognese, et al. · New England Journal of Medicine · 657
PDF
A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
2019 · Daniel M.F. Claassens, Gerrit J.A. Vos, et al. · New England Journal of Medicine · 656
PDF
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
2009 · Jessica L. Mega, Sandra L. Close, et al. · Circulation · 651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
2012 · Dietmar Trenk, Gregg W. Stone, et al. · Journal of the American College of Cardiology · 625
PDF
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention
2019 · Joo-Yong Hahn, Young Bin Song, et al. · JAMA · 624
PDF
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
2010 · Jessica L Mega, Sandra L Close, et al. · The Lancet · 615
Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents
2011 · Hyeon-Cheol Gwon, Joo-Yong Hahn, et al. · Circulation · 614
PDF
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
2017 · Dirk Sibbing, Dániel Aradi, et al. · The Lancet · 611
PDF
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
2021 · Marco Valgimigli, Enrico Frigoli, et al. · New England Journal of Medicine · 596
PDF
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
2006 · John T. Brandt, Christopher D. Payne, et al. · American Heart Journal · 572
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
2019 · Dirk Sibbing, Daniel Aradi, et al. · JACC: Cardiovascular Interventions · 538
PDF
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
2006 · Tomas Jernberg, Christopher D. Payne, et al. · European Heart Journal · 538
PDF
Primary and Secondary Prevention of Cardiovascular Disease
2012 · Per Olav Vandvik, A. Michael Lincoff, et al. · CHEST Journal · 477
PDF
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007 · L. Wallentin, C. Varenhorst, et al. · European Heart Journal · 457
PDF
Works count: 6,145
Citation count: 101,700
Year
Topic
Type